Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) (As of 12/20/2024 01:26 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends STAB vs. NAVB, EVLO, SCPS, GNCAQ, GNCA, ARDS, AMPE, CMRA, CALA, and EFTRShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Scopus BioPharma (SCPS), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Navidea Biopharmaceuticals Evelo Biosciences Scopus BioPharma Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals Comera Life Sciences Calithera Biosciences eFFECTOR Therapeutics Navidea Biopharmaceuticals (NYSE:NAVB) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends. Which has better valuation and earnings, NAVB or STAB? Navidea Biopharmaceuticals has higher earnings, but lower revenue than Statera Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K1.23-$15.18M-$0.060.00Statera Biopharma$1.49M0.00-$101.85MN/AN/A Is NAVB or STAB more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Statera Biopharma N/A N/A N/A Which has more volatility & risk, NAVB or STAB? Navidea Biopharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Do institutionals & insiders hold more shares of NAVB or STAB? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to NAVB or STAB? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Statera Biopharma Neutral Does the MarketBeat Community favor NAVB or STAB? Navidea Biopharmaceuticals and Statera Biopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes68100.00% Statera BiopharmaN/AN/A SummaryNavidea Biopharmaceuticals beats Statera Biopharma on 5 of the 6 factors compared between the two stocks. Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.1317.20Price / Sales0.00196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / BookN/A5.094.784.78Net Income-$101.85M$151.83M$120.31M$225.60M7 Day PerformanceN/A-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-75.0%$5,000.00$1.49M0.0020NAVBNavidea BiopharmaceuticalsN/AN/AN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastEVLOEvelo BiosciencesN/A$0.00flatN/A-99.1%$9,000.00N/A0.00120SCPSScopus BioPharmaN/A$0.00flatN/A-99.3%$8,000.00N/A0.009Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/AN/AN/A-99.9%$5,000.00$3.09M0.0030News CoverageAMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$3,000.00N/A0.0020Analyst ForecastCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$630,000.000.002CALACalithera BiosciencesN/A$0.00flatN/A-99.7%$1,000.00$9.75M0.0060Analyst ForecastGap DownEFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010 Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Scopus BioPharma Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Ampio Pharmaceuticals Competitors Comera Life Sciences Competitors Calithera Biosciences Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STAB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STAB Stock Alerts